ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 1042

Development of a Neo-Epitope Specific Assay for Serological Assessment of Type X Collagen Degradation and Its Potential Diagnostic Value for Knee Osteoarthritis

Yi He1, Tina Manon-Jensen2, Lars Arendt-Nielsen3,4, Kristian Petersen3, Thorbjørn Gantzel5, Jonathan Samuels6, Steven B. Abramson7, Morten A. Karsdal8, Mukundan Attur9 and Anne C. Bay-Jensen8, 1Rheumatology, Nordic Bioscience, Biomarkers and Research, Herlev, Denmark, 2Biomarkers and Research, Nordic Bioscience, Herlev, Denmark, 3Department of Health Science and Technology, Aalborg University, Aalborg, Denmark, 4C4Pain, Aalborg, Denmark, 5cOrthopedic Surgery Unit, Gentofte Hospital, Hellerup, Denmark, 6Department of Medicine, Divison of Rheumatology, NYU Langone Health, New York, NY, 7Dept of Medicine, NYU Langone Health, New York, NY, 8Nordic Bioscience, Herlev, Denmark, 9Rheumatology Research, NYU Langone Orthopedic Hospital, New York, NY

Meeting: 2018 ACR/ARHP Annual Meeting

Keywords: Biomarkers, cartilage, collagen and osteoarthritis

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Monday, October 22, 2018

Title: Osteoarthritis and Joint Biology – Basic Science Poster I

Session Type: ACR Poster Session B

Session Time: 9:00AM-11:00AM

Background/Purpose:

Phenotypic changes of chondrocytes toward hypertrophy might be fundamental in the pathogenesis of OA, of which type X collagen is a well-known marker. The purpose was to develop a specific immunoassay for quantification of a newly identified neo-epitope of type X collagen to assess its diagnostic value for radiographic knee osteoarthritis (OA).

 

Methods:  

A neo-epitope of type X collagen was identified in human urine from OA patients by liquid chromatography-mass spectrometry (LC-MS/MS). A monoclonal antibody against the neo-epitope was produced. To identify the enzyme responsible for the cleavage of Col10, articular cartilage isolated from patients who underwent total knee replacement (TKR) was cleaved by numerous proteases in vitro and immunodetected. Immunohistochemical detection of this neo-epitope was performed on human OA cartilage from femoral condyle. A specific enzyme-linked immunoassay was developed by employing the neo-epitope antibody and quantified in plasma samples of two clinical studies: the C4Pain-003 and the NYU OA progression study. ROC curve analysis was carried out to evaluate the discriminative power of Col10neo between OA and RA.

 

Results:

A mAb 2F4 targeting Cathepsin K- generated 479GIATKG neo-epitope was produced. In knee cartilage sections with mild or moderate cartilage degradation stained with Safranin O/Fast green, GIATKG neo-epitope was localized to the pericellular matrix of chondrocytes, while specimen with advanced cartilage degradation, its presence was extended to the territorial matrix of chondrocyte clusters and more prominent in superficial fibrillation. In the C4Pain study, there was a trend toward a higher level of Col10neo in subjects with greater KL. The greatest percent of subjects with KL3-4 was in the group of the highest tertile of Col10neo. In the NYU study, Col10neo was statistically higher in OA than control or RA. No significant difference was seen between control and RA (Figure 1). When adjusted for age, gender, and BMI, Col10neo remains significantly higher in OA compared to control and RA (Figure 2A). ROC curve analysis revealed area under the curve (AUC) was 0.88 (95% CI 0.81-0.94) (Figure 2B).

Fig. 1

Fig.2

Conclusion:

Our findings indicate that Col10neo could be used as a diagnostic biochemical marker for knee OA.

 


Disclosure: Y. He, Nordic Bioscience, 3; T. Manon-Jensen, Nordic Bioscience, 3; L. Arendt-Nielsen, None; K. Petersen, None; T. Gantzel, None; J. Samuels, None; S. B. Abramson, None; M. A. Karsdal, Nordic Bioscience, 1, 3; M. Attur, None; A. C. Bay-Jensen, Nordic Bioscience, 1, 3.

To cite this abstract in AMA style:

He Y, Manon-Jensen T, Arendt-Nielsen L, Petersen K, Gantzel T, Samuels J, Abramson SB, Karsdal MA, Attur M, Bay-Jensen AC. Development of a Neo-Epitope Specific Assay for Serological Assessment of Type X Collagen Degradation and Its Potential Diagnostic Value for Knee Osteoarthritis [abstract]. Arthritis Rheumatol. 2018; 70 (suppl 9). https://acrabstracts.org/abstract/development-of-a-neo-epitope-specific-assay-for-serological-assessment-of-type-x-collagen-degradation-and-its-potential-diagnostic-value-for-knee-osteoarthritis/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2018 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/development-of-a-neo-epitope-specific-assay-for-serological-assessment-of-type-x-collagen-degradation-and-its-potential-diagnostic-value-for-knee-osteoarthritis/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology